MINI FUTURE LONG - ELI LILLY & CO | Real-time Euronext Paris 14:13:36 22/05/2024 BST | ||
| 14.64 EUR | +2.56% |
|
| Current month | +17.83% | ||
| 1 month | +82.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 14.64 | +2.56% |
| 21/05/24 | 14.28 | +18.42% |
| 20/05/24 | 12.06 | +8.75% |
| 17/05/24 | 11.08 | -5.70% |
| 16/05/24 | 11.76 | -0.93% |
Real-time Euronext Paris
Last update May 22, 2024 at 02:13 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| 0K8NB | |
| ISIN | FRBNPP06JOD4 |
| Date issued | 04/03/2024 |
| Strike | 650.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 11.48 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.24 € |
|---|---|
| Lowest since issue | 6.8 € |
| Spread | 0.66 € |
| Spread % | 4.41% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- 0K8NB Certificat
